Mohs achieves up to 99% cure rates for primary BCC — with recurrence as low as 4.4% over 10 years compared to 12.2% with standard excision. Mohs examines 100% of surgical margins in real-time, produces up to 38% smaller defects than standard excision (116.6 mm² vs 187.7 mm²), and typically takes 2–4 hours in a single outpatient appointment. Serious adverse events occur in only 0.02% of cases, with infection rates among the best surgeons approaching 0.43% — well below published benchmarks of 2.5–8.7%. Mohs is the gold standard for facial cancers, recurrent tumors, and aggressive subtypes, though standard excision remains appropriate for small, low-risk BCC in less visible areas.
Evidence Snapshot
| Key Finding | Data |
|---|---|
| Primary BCC 5-Year Cure Rate | Up to 99% with Mohs vs 90–95% with standard excision |
| 10-Year Recurrence (Primary BCC) | 4.4% Mohs vs 12.2% standard excision (Dutch RCT) |
| Tissue Sparing | 38% smaller defects (116.6 mm² vs 187.7 mm²) |
| Safety Profile | Serious adverse events in 0.02% of 20,821 cases; zero deaths |
What Is Mohs Micrographic Surgery?
Mohs micrographic surgery is a specialized surgical technique for treating skin cancer — primarily basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) — that combines surgical removal with real-time microscopic examination of 100% of the surgical margins. Named after dermatologist Frederic E. Mohs, who developed the procedure in 1938, modern Mohs surgery uses fresh (unfixed) tissue and frozen-section processing rather than chemical fixatives, allowing results within 15–30 minutes.
Standard surgical excision sends tissue to an external lab where a pathologist examines approximately 1% of the actual tissue margin. Mohs examines 100% — that difference is why Mohs catches cancers that other methods miss.
How the Procedure Works
The Mohs process unfolds in distinct phases during a single outpatient appointment:
Tumor Mapping & Initial Excision The surgeon marks the visible tumor and removes it along with a thin margin of surrounding normal skin using a scalpel. The specimen is oriented and numbered on a diagram (the "surgical map") to maintain precise spatial relationships.
Preparation & Microscopic Examination Unlike standard surgery, the tissue is processed immediately on-site in the Mohs laboratory. The specimen is embedded in a cryostat (a freezing microtome), sectioned horizontally in thin slices, stained, and placed on glass slides. The surgeon then examines the entire perimeter of the tissue under a microscope, looking for any remaining cancer cells.
Real-Time Decision Making If cancer is found, the surgeon uses the surgical map to identify exactly where the remaining tumor is located and removes an additional layer from that specific area only — not from the whole wound. This layer is then processed and examined again.
Repeat Until Clear This cycle continues until the surgeon examines a complete layer with no cancer cells present on any margin. At that point, the wound is deemed cancer-free and ready for repair.
Reconstruction Once margins are confirmed clear, the wound may be closed with stitches, allowed to heal naturally (second intention healing), or reconstructed with a skin flap or graft for functional or cosmetic benefit.
This step-by-step approach differs fundamentally from standard surgical excision, where the surgeon removes the tumor and a pre-determined margin based on guidelines, then sends the specimen to a pathology lab — examining only about 1% of the actual tissue margin. Mohs examines 100% of the margin, providing certainty that cancer is removed and healthy tissue is preserved.
What Types of Skin Cancer Is Mohs Surgery Used For?
Primary Indications
Basal Cell Carcinoma (BCC) BCC is the most common skin cancer globally and the most frequent indication for Mohs surgery. Per current NCCN guidelines, MMS is appropriate for:
- Recurrent BCC (cancer returning after prior treatment)
- BCC of any size on the head, neck, hands, feet, pretibial area, or genitals
- BCC ≥2 cm on the trunk or extremities
- BCC with aggressive histologic subtypes (micronodular, basosquamous, sclerosing/morpheaform)
- BCC in the "H zone" of the face (central face, ears, eyelids, lips, nose)
- BCC in areas of critical function or cosmesis (eyelids, lips, nose, ears, fingers, genitals)
Studies demonstrate up to 99% 5-year cure rates for primary BCC treated with Mohs, compared to 90–95% for standard excision (Rowe et al., 1989; Leslie & Greenway, 1991).
Squamous Cell Carcinoma (SCC) SCC represents approximately 20% of non-melanoma skin cancers and carries higher recurrence risk than BCC, particularly in immunosuppressed patients or with aggressive subtypes (poorly differentiated, Clark level IV+, >4 mm depth). MMS is preferred for:
- Recurrent SCC
- SCC in cosmetically or functionally sensitive areas
- SCC on the face or scalp
- Large or poorly differentiated tumors
- SCC in immunosuppressed patients (transplant recipients, hematologic malignancies)
Five-year cure rates for primary SCC with Mohs range from 92–99%, versus 80–90% with standard excision (REGESMOHS, 2021; Rowe et al., 1989).
Emerging Indications
Melanoma In Situ (MIS) Mohs surgery using immunohistochemical staining (typically MART-1 or SOX10) has become an increasingly accepted approach for melanoma in situ, particularly in cosmetically sensitive areas (face, neck). The largest published series — 2,114 melanomas treated with MMS and MART-1 immunostaining — demonstrated a 0.49% local recurrence rate, with 82% of cases excised using margins of 6 mm or less (Valentín-Nogueras et al., 2016). A comparison of 662 MIS patients showed 1.8% recurrence with Mohs versus 5.7% with wide local excision over 5 years (Nosrati et al., 2017).
In the largest MART-1 Mohs series ever published (2,114 melanomas), local recurrence was just 0.49% — the lowest of any surgical approach. This technique requires a surgeon trained in both Mohs and melanoma immunopathology. Fellowship-trained Mohs surgeons who perform melanoma Mohs learn to interpret these specialized immunostains during their ACMS fellowship training.
Early-Stage Invasive Melanoma Current NCCN melanoma guidelines (v1.2026) state that MMS may be "considered selectively" for T1a melanomas in anatomically constrained areas where standard surgical margins would cause significant functional or cosmetic compromise. Modified Mohs with permanent sections and immunostaining achieves 5-year recurrence rates around 1.1–3% for thin invasive melanomas (<1 mm Breslow depth) (Valentín-Nogueras et al., 2016; Nosrati et al., 2017). This requires specialized training: the surgeon must be fellowship-trained in Mohs surgery and experienced in melanoma immunopathology, skills developed during ACMS-accredited fellowship programs that include immunostain interpretation as part of melanoma Mohs training.
Other Tumors Mohs is occasionally used for other high-risk skin cancers or tumors in critical locations, including dermatofibrosarcoma protuberans (DFSP), atypical fibroxanthoma, extramammary Paget disease, and lymphomas of the skin, though evidence is limited for most.
How Does Mohs Surgery Compare to Other Treatments?
| Factor | Mohs Surgery | Standard Surgical Excision | Superficial Radiation (SRT) |
|---|---|---|---|
| 5-Year Cure Rate (Primary BCC) | Up to 99% | 90–95% | ~95% |
| 10-Year Recurrence (Primary BCC) | 4.4% | 12.2% | ~8–10% |
| Margin Verification | 100% of margin examined | ~1% of margin examined | No histologic margin control |
| Tissue Conservation | Maximal (116.6 mm² median defect) | Moderate (187.7 mm² median defect) | Variable (depends on field size) |
| Reconstruction | Often needed; surgeon controls closure | Often needed; second closure | Rarely needed |
| Average Cost | $2,000–$4,500 | $1,000–$2,500 | $2,500–$8,000+ (course of treatment) |
| Treatment Duration | Single appointment, 2–4 hours | Single appointment, 30–60 min | 3–5 weeks, multiple visits |
| Best For | BCC/SCC in face, ears, eyelids, nose, lips; recurrent tumors; aggressive subtypes | Small, primary BCC in low-risk areas; trunk/extremities | Elderly or medically unfit patients; extensive areas; superficial lesions |
| Evidence Level | Level 1 (RCTs, prospective cohorts) | Level 2–3 (historical series) | Level 2–3 (cohort studies) |
| Risk of Incomplete Excision | Minimal | Moderate (1–10% depending on location) | N/A (non-surgical) |
| Cosmetic Outcome | Excellent (tissue sparing) | Good (but larger defect) | Good–Fair (may have radiation changes) |
The "gold standard" designation for Mohs reflects its superior combination of cure rate, tissue sparing, and margin certainty. Standard excision remains appropriate for low-risk primary BCC in less visible areas where tissue conservation is less critical. For a detailed comparison of Mohs vs radiation therapy, see our dedicated comparison guide.
What to Expect Before, During, and After Mohs Surgery
Pre-Operative Medication Policy
One of the most common patient questions involves whether to stop medications before surgery. Based on large published datasets and clinical experience, here is the evidence-based approach:
| Medication | Recommendation | Why |
|---|---|---|
| Aspirin | CONTINUE | Stopping increases cardiovascular event risk; bleeding is manageable |
| Fish oil | CONTINUE | No evidence of clinically meaningful bleeding risk |
| Ibuprofen/NSAIDs | CONTINUE | Risk of stopping outweighs minimal bleeding increase |
| Blood thinners (warfarin, Eliquis, Xarelto, Plavix) | CONTINUE unless your cardiologist or prescribing physician directs otherwise | Stopping creates dangerous clotting risk; Mohs bleeding is controllable |
Stopping blood thinners for skin surgery can cause strokes and heart attacks. The evidence is clear: the bleeding risk from continuing is manageable; the clotting risk from stopping can be fatal. Any surgeon asking you to stop anticoagulation without consulting your cardiologist is not following current evidence.
Day of Surgery
Plan for a full day. Eat a normal breakfast, take your usual medications, and wear comfortable, loose-fitting clothing. Bring a book or device — there is waiting time between tissue processing stages. Most patients experience minimal discomfort during the procedure, as the area is numbed with local anesthesia.
Recovery
Mohs surgery is outpatient. Plan to rest for 2–3 days, avoiding strenuous activity and heavy lifting. Keep the wound clean and dry. Stitches are removed at 7–14 days depending on location. Expect mild pain (controlled with over-the-counter acetaminophen or ibuprofen), swelling (peaks at 24–48 hours), and possibly bruising. Most patients return to normal activities by day 10–14.
What a Surgeon's Outcomes Should Tell You
Not all Mohs surgeons achieve the same results. Published outcome data allows you to compare your surgeon's track record against evidence-based benchmarks. Ask your surgeon about their infection rates, recurrence rates, and experience with your specific tumor type. For more on evaluating a Mohs surgeon, see our guide to choosing a Mohs surgeon.
What the Evidence Shows: A Surgeon's Perspective
As a triple board-certified Mohs surgeon with 23,000+ cases and approximately 300 melanoma cases per year, here is my clinical perspective on when Mohs surgery is — and is not — the right choice.
For Facial Basal Cell & Squamous Cell Carcinoma The evidence is unequivocal. A decade-long randomized controlled trial from the Netherlands — the highest quality surgical evidence available — showed 4.4% recurrence with Mohs versus 12.2% with standard excision for primary facial BCC at 10 years (van Loo et al., 2014). For recurrent tumors, the gap widens to 3.9% versus 13.5%. That is a 3-fold reduction in recurrence risk and substantially better cosmetic outcomes because Mohs removes only what is necessary.
For High-Risk Subtypes Aggressive BCC subtypes (micronodular, basosquamous, morpheaform) or poorly differentiated SCC have higher recurrence rates overall. Mohs's real-time microscopy allows identification of these aggressive patterns and adjustment of the excision strategy, rather than hoping a standard margin was adequate. This is especially important in immunosuppressed patients, where SCC recurrence rates can exceed 30% without careful assessment.
For Tissue Conservation The first randomized trial demonstrating tissue-sparing benefits showed Mohs produces 38% smaller defects than standard excision (116.6 mm² vs 187.7 mm²) while achieving better cure rates (Muller et al., 2009). For eyelids, lips, ears, and nose — areas where function and appearance matter profoundly — this difference is clinically meaningful.
For Melanoma In Situ Mohs with immunohistochemical staining is emerging as an excellent option for facial melanoma in situ. The published recurrence rate of 1.1–1.8% over 5 years is competitive with or superior to wide local excision (Nosrati et al., 2017), with the added benefit of tissue sparing. This requires specialized training and should only be performed by experienced Mohs surgeons familiar with melanoma pathology and immunostaining interpretation.
For Recurrent Tumors Standard excision fails 10–13% of recurrent BCCs (van Loo et al., 2014). Once a tumor has recurred, the risk is higher for multiple reasons: field effects, aggressive biology, or inadequate prior treatment. Mohs's 100% margin control is critical here.
Why Dermatologist-Performed Mohs Produces the Best Outcomes Mohs surgery is unique in medicine: the same physician serves as surgeon, pathologist, and reconstructive surgeon — all in one appointment. This requires triple expertise that only fellowship-trained Mohs dermatologists possess. A 2025 JAMA review confirmed that Mohs achieves the lowest local recurrence rates for both BCC (3.8%) and SCC (2.8%) of any treatment modality — substantially better than standard excision performed by any specialty. The 2024 JEADV meta-analysis of 17 studies found a BCC-specific relative risk of 0.37 favoring Mohs over conventional surgery. The AAD position statement (2021) is explicit: surgical management by trained dermatologic surgeons remains the most effective treatment for BCC and SCC.
When Standard Excision Is Appropriate Mohs is not necessary for every skin cancer. For small, primary, low-risk BCC on the trunk or extremities — areas where tissue conservation matters less — standard excision is entirely appropriate and more cost-effective. Shared decision-making is essential; a patient's preference for simpler, faster surgery should be respected if the cancer risk is genuinely low.
Related Articles
- Complete Guide to Melanoma: Detection, Staging & Treatment
- Basal Cell Carcinoma: Types, Treatment & Prevention
- Squamous Cell Carcinoma: What You Need to Know
- How to Choose a Mohs Surgeon
- Mohs Surgery vs Radiation (SRT)
- Surgical Margins in Mohs, BCC & SCC
- Blood Thinners and Skin Cancer Surgery
- Estimate Your Skin Cancer Risk
Test Your Mohs Surgery Knowledge
4 game modes to test what you've learned. Pick your style.
Choose your mode
Take your time. Get detailed explanations after each question.
15-second timer. Score points for speed. Build streaks for multipliers.
Pick your category. Pick your value. How much do you know?
Progressive difficulty. 3 lifelines. How far can you go?
Frequently Asked Questions
1. How long does Mohs surgery take?
Most Mohs procedures take 2–4 hours from arrival to departure. This includes initial examination (15–20 min), first excision (20–30 min), and laboratory processing and examination (15–30 min per stage). If clear margins are found in the first stage, the procedure may take as little as 1–1.5 hours. If additional stages are needed (typically 1–3 more), each adds 30–45 minutes. Reconstruction time varies: simple closure may add 15 minutes, while flap or graft reconstruction can add 1–2 hours.
2. Will I need stitches? Can the wound be left open?
After clear margins are confirmed, options include:
- Primary closure (stitches): The most common approach. Stitches are removed in 7–14 days depending on location.
- Flap reconstruction: Tissue from nearby skin is rotated or advanced to fill the defect, providing excellent cosmetics for larger wounds, especially on the nose, ear, or lip.
- Skin graft: Skin from another body area is sutured into place for large defects. Grafts require a bolster dressing for 1–2 weeks.
- Second intention healing: The wound heals from the bottom up. This works well for small defects on the scalp, ear, or temple, but takes 4–12 weeks.
Your surgeon will discuss options based on defect size, location, and your preferences.
3. How much does Mohs surgery cost?
Cost varies by geography, tumor complexity, and whether reconstruction is needed. Typical ranges are $2,000–$4,500 for the entire procedure, including the surgical fee, pathology, facility, and simple closure. Reconstruction (flap or graft) may add $500–$2,000. Most insurance plans cover Mohs for appropriate indications. If you are uninsured, ask about financial counseling options before your procedure.
4. Will there be a scar?
All surgery leaves a scar, but Mohs's tissue-sparing approach often results in smaller, less noticeable scars than standard excision. Initial scars are pink or purple and fade over 6–12 months. Scars on the face typically heal better cosmetically than on the chest or shoulder, where tension and sun exposure can worsen appearance. Most patients find the cosmetic outcome of Mohs acceptable or excellent.
5. Can Mohs be used on the eyelid or lip?
Yes. Mohs is increasingly preferred for BCC and SCC on the eyelid, lip, and perioral area because these are cosmetically critical zones and preserving function is paramount. Published series show excellent outcomes in these areas, though specialized reconstruction techniques may be needed.
6. What is the difference between standard Mohs and "modified" Mohs for melanoma?
Standard Mohs uses conventional histology (H&E staining) and frozen sections oriented horizontally. Modified Mohs for melanoma uses immunohistochemical stains (MART-1, SOX10) to highlight melanoma cells more clearly, and may use en face sectioning to assess the full thickness of the specimen. This approach was developed because melanoma cells can be subtle on routine H&E. Modified Mohs for melanoma should only be performed by surgeons with specific training in melanoma immunopathology.
7. Is Mohs surgery safe? What are the risks?
Mohs is among the safest surgical procedures in medicine. Serious adverse events occur in only 0.02% of cases across 20,821 procedures, with zero deaths reported (Alam et al., 2013). The most common complications are mild:
- Infection (~0.43–2.5%): Usually managed with oral antibiotics.
- Bleeding/hematoma (~0.2–1%): Typically controlled with pressure or cautery.
- Wound dehiscence (separation of stitches): Rare, managed with re-closure.
- Nerve/blood vessel injury: Rare but possible near anatomically important structures (e.g., facial nerve, labial artery).
Patients on blood thinners can safely undergo Mohs with appropriate precautions. Discuss all medications with your surgeon beforehand.
8. Why does Mohs cost more than standard excision?
Mohs requires the surgeon to also serve as the pathologist — examining every tissue section in real-time. This dual expertise, along with dedicated lab equipment (cryostat, microscope) and same-day processing, drives the higher cost. From a value perspective, lower recurrence reduces the likelihood of needing re-treatment, meaning Mohs often provides better long-term value despite higher upfront costs.
9. Can anyone perform Mohs surgery?
No. Mohs micrographic surgery requires specialized training beyond dermatology residency. In the U.S., dermatologists complete a 1–2 year ACMS (American College of Mohs Surgery)-accredited fellowship, which is also ACGME-accredited. Completion of this fellowship makes surgeons eligible for ABMS board certification in Micrographic Surgery and Dermatologic Oncology (MSDO), administered by the American Board of Dermatology. There are fewer than 30 triple board-certified Mohs surgeons (Dermatology; Dermatopathology; and MSDO) in the world. Learn how to evaluate a Mohs surgeon's credentials →
10. What if Mohs shows cancer in the deep margin?
This is uncommon but important. If Mohs examination reveals tumor at the deepest margin, the surgeon typically:
- Notes the area on the surgical map.
- Requests permanent section histology to fully assess the deep margin.
- May refer the patient for adjunctive radiation therapy or extended follow-up.
- Documents the finding and counsels the patient on surveillance and potential future re-excision.
This scenario accounts for less than 1% of cases and does not invalidate Mohs's benefit for margin control.
11. How often do cancers come back after Mohs?
Recurrence rates depend on tumor type and patient factors:
- Primary BCC: 1.0–4.4% over 5–10 years (vs. 10.1–12.2% with standard excision)
- Recurrent BCC: 2.4–3.9% over 5–10 years (vs. 13.5% with standard excision)
- Primary SCC: 1.3–4.5% per 100 person-years (vs. 10.9% with standard excision)
- Melanoma in situ: 1.1–5.7% over 5 years (comparable to wide local excision)
Risk factors for recurrence include age, immunosuppression, location, and tumor subtype. Most recurrences appear within 2–5 years but can occur later. This is why long-term surveillance (at least 5–10 years) is recommended.
About the Author
Thomas L.H. Hocker, M.D., M.Phil. is a triple board-certified dermatologist, dermatopathologist, and Mohs micrographic surgeon. He trained at Harvard Medical School and Mayo Clinic.
About This Site
Skin Trust is a free educational website created by Dr. Thomas L.H. Hocker, M.D., M.Phil. to make dermatologic knowledge accessible to patients and healthcare professionals. All content is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Skin Trust is Dr. Hocker's independent educational work, completely unaffiliated with any medical practice, healthcare system, hospital, university, or organization. Using this website does not create a doctor-patient relationship. If you have or suspect you have a medical condition, consult a qualified healthcare provider. Never delay seeking professional care based on information from this site.
References
Leslie DF, Greenway HT. Mohs Micrographic Surgery for skin cancer. Australas J Dermatol. 1991;32(3):159-164. PMID: 1823112
Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989;15(3):315-328. PMID: 2646336
van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer. 2014;50(17):3011-3020. PMID: 25262378
Mosterd K, Krekels GA, Nieman FH, et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol. 2008;9(12):1149-1156. PMID: 19010733
Bene NI, Healy C, Coldiron BM. Mohs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases. Dermatol Surg. 2008;34(5):660-664. PMID: 18261099
Muller FM, Dawe RS, Moseley H, Fleming CJ. Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome. Dermatol Surg. 2009;35(9):1349-1354. PMID: 19500127
Alam M, Goldberg LH, Silapunt S, et al. Adverse events associated with mohs micrographic surgery: a multicenter prospective cohort study of 20,821 cases at 23 centers. JAMA Dermatol. 2013;149(12):1378-1385. PMID: 24080866
Tomás-Velázquez A, Sanmartin-Jiménez O, Garcés JR, et al. Risk Factors and Rate of Recurrence after Mohs Surgery in Basal Cell and Squamous Cell Carcinomas: A Nationwide Prospective Cohort (REGESMOHS, Spanish Registry of Mohs Surgery). Acta Derm Venereol. 2021;101(10):adv00571. PMID: 34694418
Nosrati A, Berliner JG, Goel R, et al. Outcomes of Melanoma In Situ Treated With Mohs Micrographic Surgery Compared With Wide Local Excision. JAMA Dermatol. 2017;153(5):436-441. PMID: 28241261
Valentín-Nogueras SM, Brodland DG, Zitelli JA, González-Sepúlveda L, Nazario CM. Mohs Micrographic Surgery Using MART-1 Immunostain in the Treatment of Invasive Melanoma and Melanoma in Situ. Dermatol Surg. 2016;42(6):733-744. PMID: 27158886
Murray C, Sivajohanathan D, Hanna TP, et al. Patient Indications for Mohs Micrographic Surgery: A Systematic Review. J Cutan Med Surg. 2019;23(1):75-90. PMID: 30033747
